Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Antipsychotics
6 evidence topics · 8 sources
EHDN international guideline: second-generation neuroleptics for chorea and psychiatric symptoms
German Neurological Society guideline: tiapride as first-line antichoreic treatment
“Because of the favorable profile of side effects, in particular with regard to extrapyramidal (akathisia, Parkinsonism) and behavioral (depression) symptoms, the consensus in the Delphi group was that tiapride should be considered as first line treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparative studies (comparing head-to-head compounds for their ability to suppress hyperkinesias short- and long-term) are unavailable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAN guideline (retired 2022): insufficient data for neuroleptics
HDSA physician's guide: off-label neuroleptics for chorea
International expert survey: first-choice antichoreic drug by region
“However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote